My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Recombinant In Vivo Grade Anti-Mouse CD8a Monoclonal Antibody (Clone: 53-6.72)

Recombinant In Vivo Grade Anti-Mouse CD8a Monoclonal Antibody (Clone: 53-6.72)

T-cell surface glycoprotein Lyt-2, CD8 alpha, T-cell surface glycoprotein CD8 alpha chain, CD_antigen CD8a

Catalog No. Product Name Size List Price (US$) Quantity
PA007533.r2a In Vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 53-6.72), Rat IgG2a Kappa 1 mg 150.00
PA007533.r2a In Vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 53-6.72), Rat IgG2a Kappa 5 mg 350.00
PA007533.r2a In Vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 53-6.72), Rat IgG2a Kappa 25 mg 900.00
Description

Background of Recombinant In Vivo Grade Anti-Mouse CD8a Antibody (Clone: 53-6.72)

Our Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone: 53-6.72) represents a sequence-defined, mammalian-expressed technological upgrade specifically engineered to eliminate the inherent biological vulnerabilities of legacy hybridoma-derived reagents. This premium In Vivo Grade Anti-Mouse CD8a Antibody precisely targets the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain), a critical orchestrator of cell-mediated immune defense and T-cell ontogeny. By leveraging advanced recombinant engineering, our Anti-Mouse CD8a Clone 53-6.72 retains the exact, high-fidelity variable regions or complete amino acid sequences of the classic rat IgG2a kappa clone. Unlike traditional hybridoma lines that are notoriously prone to genetic drift, unexpected mutations, and contamination with non-specific endogenous light chains, this recombinant mouse CD8a antibody guarantees absolute batch-to-batch consistency and structural purity, ensuring unparalleled reproducibility in long-term screening campaigns.

In functional immunology and oncology modeling, the classic Anti-CD8a Clone 53-6.7 has established itself as the gold-standard workflow for targeting malignant pathways and executing in vivo CD8a+ T cell depletion assays. However, introducing external monoclonal reagents into live animal models demands stringent safety thresholds to prevent catastrophic non-specific immune activation or subject mortality. To address this paradigm, Syd Labs subjects this low endotoxin anti-mouse CD8a antibody to meticulous purification processes, enforcing ultra-low endotoxin specifications and a complete absence of problematic protein aggregates. By explicitly aligning superior batch reproducibility with uncompromising in vivo safety, our recombinant platform ensures that your in vivo cell depletion and T-cell tracking profiles generate clean, publication-ready datasets, entirely free from confounding systemic side effects. Our In Vivo Grade Anti-Mouse CD8a Antibody (Clone: 53-6.72) is specifically formulated and optimized for functional in vivo CD8a+ T cell depletion in live models. For analytical applications such as cell surface staining, immunophenotyping, or tissue mapping, we highly recommend our dedicated Recombinant Anti-Mouse CD8a Antibody for Flow Cytometry. This FACS-optimized alternative offers Human IgG1 Fc Silent™ and Biotinylated Avi-Tag formats to minimize background noise and ensure pristine FACS gating profiles.

PA007533.r2a: In Vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 53-6.72), Rat IgG2a Kappa

Recombinant rat IgG2a Monoclonal Antibody.
Synonyms: CD8a, CD8 alpha, Lyt-2, Lyt2 alpha, Ly-2.
Clone: 53-6.72.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: 53-6.72) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: 53-6.72) specifically binds to mouse CD8a.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD8a protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
RRID: AB_3751529

Shipping: The in vivo grade recombinant anti-mouse CD8a monoclonal antibody of clone 53-6.72 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References for Anti-Mouse CD8a Monoclonal Antibody (Clone: 53-6.72)

Key Application: In vivo CD8+ T cell depletion (500 µg/mouse, i.p.) to mitigate cytokine storms and analyze respiratory immunopathology.
Walsh, K. B., et al. J Virol. 2014 Jun;88(11):6281-93. PMID: 24672024
In this study, cell surface profiling and targeted cell elimination protocols were utilized to investigate severe respiratory immune pathologies. For functional in vivo cell depletion experiments, a specific high-dose regimen consisting of 500 µg of anti-mouse CD8 antibody (Clone: 53-6.72 / 53-6.7) was administered intraperitoneally (i.p.) to mice to selectively ablate targeted cytotoxic T cell populations prior to and during infection. Single-cell suspensions from harvested lungs and mesenteric lymph nodes were analyzed ex vivo, demonstrating that the targeted depletion of CD8+ T cells effectively tracted the downstream progression of virus-induced cytokine storms and significantly altered intracellular IFN-γ and granzyme B production profiles.
(Tags: In Vivo Grade Anti-Mouse CD8a Antibody; Anti-Mouse CD8a Clone 53-6.72; In Vivo CD8a+ T Cell Depletion; Low Endotoxin Anti-Mouse CD8a)
Key Application: Target-specific in vivo depletion of memory/effector CD8+ T cell clonal expansions during chronic bacterial infection tracking.
Cyktor, J. C., et al. PLoS One. 2013;8(3):e58612. PMID: 23472214
To characterize protective immune mechanics against chronic Mycobacterium tuberculosis (Mtb) exposure, researchers evaluated the functional role of pulmonary T cell sub-populations. An anti-CD8+ (Clone: 53-6.72) depletion monoclonal antibody formulation was diluted to a working concentration of 2.5 mg/ml in sterile PBS, stored at -80°C, and deployed for targeted in vivo depletion of specific T cell clonal populations during chronic stages of infection. The successful removal of these cells led to a measurable reduction of pathogenic IL-10 levels in the lung tissues, proving the precise biological impact of the 53-6.72 clone in dissecting the role of protective IFN-γ-producing and regulatory CD8+ T cells within live animal models.
(Tags: Anti-Mouse CD8a Clone 53-6.72 mAb; Recombinant Mouse CD8a Antibody; CD8 T Cell Depletion In Vivo)
Key Application: Functional in vivo evaluation of pathogenic CD8+ T cell responses and blood-brain barrier disruption via monoclonal antibody blockade.
Hafalla, J. C. R., et al. PLoS Pathog. 2012 Feb;8(2):e1002504. PMID: 22319445
This study establishes that cytotoxic CD8+ T cells and downstream inflammatory cytokines like IFN-γ are primary drivers of acute immune pathologies and experimental cerebral malaria (ECM) pathogenesis. The destructive mechanism demonstrates that pathogenic CD8+ T cells damage cerebral vascular endothelial cells and breach the blood-brain barrier, resulting in severe hemorrhages and edema. Functional blocking or targeted cell removal via systemic administration of anti-mouse CD8a monoclonal antibodies (Clone: 53-6.72 / 53-6.7) serves as the gold-standard analytical model to dampen these aggressive T cell responses, allowing researchers to accurately map how the checkpoint pathways PD-1/PD-L1 and CTLA-4 independently modulate host resistance in cancer research and complex infection models.
(Tags: Anti-CD8a Clone 53-6.7; Anti-Mouse CD8a 53-6.72 in Animal Model; Low Endotoxin Anti-Mouse CD8a)
For more technical references or data sheets regarding the Recombinant Anti-Mouse CD8a Monoclonal Antibody formats, please contact our scientific support team at message@sydlabs.com.

Frequently Asked Questions (FAQ) about Recombinant Anti-Mouse CD8a Antibody (Clone: 53-6.72 / 53-6.7)

Q: Is this antibody fully validated for highly efficient in vivo CD8a+ T cell depletion assays?

Yes. Our In Vivo Grade Anti-Mouse CD8a Antibody is thoroughly validated for systemic administration to achieve comprehensive, targeted in vivo cd8 depletion clone 53-6.7 equivalent results in murine models. Standard published protocols typically utilize an intraperitoneal (i.p.) injection of 100 µg to 500 µg of the purified antibody per mouse. This dosing regimen effectively ablates cytotoxic T cell populations within peripheral blood, spleen, and lymph nodes for multiple days, making it an ideal choice for immune-mediated infection modeling and oncology screenings.

Q: What is the recommended mouse CD8+ T cell depletion protocol and clone 53-6.7 injection dosage in vivo?

For an optimal mouse cd8+ t cell depletion protocol, we recommend an initial clone 53-6.7 injection dosage in vivo (utilizing our recombinant 53-6.72 format) ranging from 100 µg to 250 µg per mouse via intraperitoneal (i.p.) administration. Because this antibody features a highly effective rat igg2a anti mouse cd8 depletion isotype, it successfully triggers host Fc-mediated effector functions (such as ADCC and CDC) to clear target cells. Maintenance doses of 100 µg can be administered every 2-3 days depending on your experimental window. We advise verifying depletion efficiency via flow cytometry of peripheral blood or spleen 48-72 hours post-injection.

Q: Why should I choose the recombinant version of Clone 53-6.72 over traditional hybridoma-derived alternatives?

Traditional hybridoma lines are highly susceptible to genetic drift, chromosomal loss, or contamination with non-specific endogenous myeloma light chains. Our Recombinant Anti-Mouse CD8a Monoclonal Antibody is sequence-defined and expressed under strict serum-free mammalian cell culture conditions. This cutting-edge platform guarantees 100% batch-to-batch structural integrity, superior reproducible binding profiles, and eliminates unwanted non-specific background signals, allowing long-term research cohorts to generate pristine, publication-ready datasets.

Q: What is the endotoxin profile and formulation buffer of your in vivo grade CD8a antibody?

To prevent lethal cytokine storms or non-specific physiological inflammation in live subjects, our premium low endotoxin anti-mouse cd8 53-6.7 equivalent antibody undergoes stringent multi-step purification protocols. It features a guaranteed ultra-low endotoxin threshold (<1 EU/mg) and is formulated as a 0.2 µM filtered solution in 1x PBS. The composition is entirely free of sodium azide, carrier proteins, or stabilizing preservatives, meeting the strict requirements for clean, toxicity-free animal injections.

Q: What is the biological difference between anti-mouse CD8a clone 53-6.72 and clone 53-6.7?

Biochemically and functionally, there is no structural difference in antigen recognition between the two names. The designation 53-6.72 represents the complete cloned subline nomenclature of the classic Anti-CD8a Clone 53-6.7. Our advanced Anti-Mouse CD8a Clone 53-6.72 possesses the exact high-fidelity variable domains that specifically bind the mouse CD8 alpha chain. It seamlessly substitutes for any academic or industrial protocol historically established with the 53-6.7 designation while bringing the upgraded stability of a recombinant expression framework.

Q: Are bulk quantities or custom engineered formats available for this recombinant mouse CD8a antibody?

Yes. Syd Labs specializes in high-yield bioprocess scale-up to support translational medicine and large-scale industrial platforms. We provide customized, bulk-packaged aliquots of our Recombinant Mouse CD8a Antibody upon request. Additionally, we provide professional engineering options including specific species/isotype chimerization, targeted Fc silencing (e.g., LALAPG mutants to abolish non-specific Fc-receptor engagement), recombinant affinity tagging, and direct enzyme or fluorophore conjugations.

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)

Related Links

See our Privacy Policy